Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their ...

Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the ...

Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency ...

Shares of Biogen Inc. BIIB advanced 2.06% to $118.89 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 2.51% to 5,287.76 and ...

The Trump administration is expected to announce tariffs on pharmaceuticals "in the next month or two," an official said. | The Trump administration is expected to announce tariffs on pharmaceuticals ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to ...

32 pharma companies demanded more favorable policies in order for them to maintain operations in the EU amid the threat of ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) ...

This summary of health news briefs includes reports on how the U.S.-China trade war impacts drug costs, EU approval of ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...